DK2205575T3 - Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion - Google Patents

Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion

Info

Publication number
DK2205575T3
DK2205575T3 DK08843687.8T DK08843687T DK2205575T3 DK 2205575 T3 DK2205575 T3 DK 2205575T3 DK 08843687 T DK08843687 T DK 08843687T DK 2205575 T3 DK2205575 T3 DK 2205575T3
Authority
DK
Denmark
Prior art keywords
sulfonamide
inhibitor
peptide production
acetamide compound
new alpha
Prior art date
Application number
DK08843687.8T
Other languages
Danish (da)
English (en)
Inventor
Jr John E Starrett
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2205575(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2205575T3 publication Critical patent/DK2205575T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK08843687.8T 2007-10-31 2008-10-14 Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion DK2205575T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
PCT/US2008/079798 WO2009058552A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
DK2205575T3 true DK2205575T3 (da) 2011-07-11

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08843687.8T DK2205575T3 (da) 2007-10-31 2008-10-14 Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion
DK10190591.7T DK2295417T3 (da) 2007-10-31 2008-10-14 Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10190591.7T DK2295417T3 (da) 2007-10-31 2008-10-14 Nye mellemprodukter, som kan anvendes til fremstilling af alpha-(n-sulfonamid)acetamidforbindelse

Country Status (28)

Country Link
US (2) US8084477B2 (https=)
EP (3) EP2205575B1 (https=)
JP (1) JP5460605B2 (https=)
KR (1) KR20100075575A (https=)
CN (2) CN101910141B (https=)
AR (1) AR069135A1 (https=)
AT (1) ATE502022T1 (https=)
AU (1) AU2008319122A1 (https=)
BR (1) BRPI0818837A2 (https=)
CA (1) CA2704360A1 (https=)
CL (1) CL2008003271A1 (https=)
CO (1) CO6270332A2 (https=)
CY (2) CY1112337T1 (https=)
DE (1) DE602008005636D1 (https=)
DK (2) DK2205575T3 (https=)
EA (2) EA201171439A1 (https=)
ES (2) ES2390042T3 (https=)
HR (2) HRP20110219T1 (https=)
IL (1) IL205406A0 (https=)
MX (1) MX2010004319A (https=)
NZ (1) NZ584545A (https=)
PE (1) PE20091394A1 (https=)
PL (2) PL2205575T3 (https=)
PT (2) PT2295417E (https=)
SG (2) SG174044A1 (https=)
SI (2) SI2295417T1 (https=)
TW (1) TW200927099A (https=)
WO (1) WO2009058552A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
JP2012520875A (ja) * 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−(n−スルホンアミド)アセトアミド化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
BR122017023123B1 (pt) 2010-03-12 2018-04-24 Nippon Soda Co., Ltd. Método para produzir derivado de picolina halogenada
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2643299B1 (en) 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
MX390370B (es) 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL123901A (en) 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
EP0939629A4 (en) 1996-07-22 2002-07-17 Monsanto Co THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
IL144347A0 (en) 1999-01-27 2002-05-23 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
WO2000050391A1 (en) * 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
IL159140A0 (en) * 2001-12-14 2004-06-01 Raytheon Co Precisely aligned lens structure and a method for its fabrication
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
IL163643A0 (en) * 2002-02-28 2005-12-18 Astrazeneca Ab Oxazolidinone derivatives, processes for their forpreparation, and pharmaceutical compositions containing them
EP1460070B1 (en) * 2003-03-20 2007-05-16 Santhera Pharmaceuticals (Schweiz) AG Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
BRPI0408962A (pt) 2003-03-31 2006-04-04 Wyeth Corp inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
US7838550B2 (en) 2006-02-17 2010-11-23 Wyeth Llc Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
HK1141801A1 (en) 2010-11-19
HRP20110219T1 (hr) 2011-04-30
AU2008319122A1 (en) 2009-05-07
PE20091394A1 (es) 2009-09-25
JP2011502153A (ja) 2011-01-20
PL2205575T3 (pl) 2011-09-30
EP2295417B1 (en) 2012-07-04
IL205406A0 (en) 2010-12-30
DK2295417T3 (da) 2012-10-15
CY1112337T1 (el) 2015-12-09
PT2205575E (pt) 2011-05-23
CN102718689A (zh) 2012-10-10
CN101910141B (zh) 2012-12-19
SG174044A1 (en) 2011-09-29
EP2295417A1 (en) 2011-03-16
US20090111858A1 (en) 2009-04-30
BRPI0818837A2 (pt) 2015-04-22
US20120088925A1 (en) 2012-04-12
ES2390042T3 (es) 2012-11-06
EA201171439A1 (ru) 2012-05-30
DE602008005636D1 (de) 2011-04-28
CL2008003271A1 (es) 2009-07-10
HRP20120703T1 (hr) 2012-09-30
US8084477B2 (en) 2011-12-27
PL2295417T3 (pl) 2012-11-30
NZ584545A (en) 2011-04-29
EA016447B1 (ru) 2012-05-30
ATE502022T1 (de) 2011-04-15
HK1155161A1 (en) 2012-05-11
SG174043A1 (en) 2011-09-29
ES2361283T3 (es) 2011-06-15
US8350084B2 (en) 2013-01-08
MX2010004319A (es) 2010-04-30
AR069135A1 (es) 2009-12-30
CA2704360A1 (en) 2009-05-07
EP2205575B1 (en) 2011-03-16
TW200927099A (en) 2009-07-01
EA201000714A1 (ru) 2010-10-29
EP2205575A1 (en) 2010-07-14
EP2471769A1 (en) 2012-07-04
CO6270332A2 (es) 2011-04-20
CY1113346T1 (el) 2016-06-22
CN101910141A (zh) 2010-12-08
SI2295417T1 (sl) 2012-11-30
PT2295417E (pt) 2012-09-26
KR20100075575A (ko) 2010-07-02
JP5460605B2 (ja) 2014-04-02
SI2205575T1 (sl) 2011-07-29
WO2009058552A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
DK2205575T3 (da) Ny alpha-(n-sulfonamid)acetamid-forbindelse som inhibitor af betaamyloidpeptid-produktion
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2049491T3 (da) Heteroaryl-sammensætninger anvendelige som inhibitorer af enzymer, der aktiverer E1
NO20084758L (no) Sammensetninger anvendelige som inhibitorer av spenningsstyrte natriumkanaler
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2081895T3 (da) Hydrobenzamidderivater som hæmmere af hsp90
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1981859T3 (da) Fremstilling af delmopinol
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
DK2120579T3 (da) Inhibitorer af poly(ADP-ripose)polymerase
DK2086960T3 (da) Nye inhibitorer af glutaminylcyclase.
DK2061465T3 (da) Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK1928872T3 (da) Hidtil ukendte sulfonylpyrroler som inhibitorer af hdac
DK2504332T4 (da) Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2032535T3 (da) Spiro-cycliske nitriler som protease-inhibitorer
DK1999133T3 (da) Fremgangsmåde til fremstilling af HIV-proteaseinhibitorer
EP2140877A4 (en) NEW USE OF COCCIDIAN
DK2178900T3 (da) Oprensning af pegylerede polypeptider
DK1948643T3 (da) 3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer
DK1917227T3 (da) Krystalformer af astaxanthin
DK2167124T3 (da) Anvendelse af monomycolylglycerol (MMG) som adjuvans